https://www.selleckchem.com/products/bay-218.html
ctions in enrollment size required (n = 25➔n = 13) to detect the observed increases in sTIL/PD-L1. mIF is useful for quantifying treatment-related dynamic changes in sTILs/PD-L1 and is concordant with clinical assays, but with greater precision. Hierarchical linear modeling can mitigate the effects of intratumoral heterogeneity on immune cell count estimations, allowing for more efficient detection of treatment-related pharmocodynamic effects in the context of clinical trials. NCT02950259 . NCT02950259 . T cell Ig and ITIM domain (TIGIT
Like
Comment
Share
